Scientists at Weill Cornell have uncovered how prostate cancer hijacks the normal function of the androgen receptor protein to fuel its growth.
This protein usually acts as both a growth accelerator and a brake in healthy prostate cells. However, in cancer cells, the brake function is suppressed, leading to uncontrolled cell multiplication.
Researchers discovered a set of genes that, when activated by the androgen receptor, can stop the growth of prostate cancer cells, but not healthy ones.
This finding could lead to new diagnostic tests to predict patient outcomes and guide treatment. It also opens up the possibility of developing therapies that reactivate the growth-suppressing function of the androgen receptor to halt cancer progression.